Mancuso ME - Search Results

This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Save citations to file

Email citations

Subject: Mancuso ME - PubMed

To:

From:

Selection:

Format:

MeSH and other data

Add to Collections

Add to My Bibliography

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Email: (change)

Frequency:

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Results by year

Year	Number of Results
2005	3
2006	5
2008	6
2009	10
2010	5
2011	3
2012	8
2013	10
2014	6
2015	16
2016	22
2017	15
2018	14
2019	11
2020	26
2021	25
2022	20
2023	18
2024	9

194 results

Page of 20

Results by year

Page 1

Simoctocog alfa (Nuwiq^®) in children: early steps in life's journey for people with severe hemophilia A.

Klukowska A, Sidonio RF Jr, Young G, Mancuso ME, Álvarez-Román MT, Bhatnagar N, Jansen M, Knaub S. Klukowska A, et al. Among authors: mancuso me. Ther Adv Hematol. 2024 May 9;15:20406207241245511. doi: 10.1177/20406207241245511. eCollection 2024. Ther Adv Hematol. 2024. PMID: 38737006 Free PMC article. Review.

Long-term efficacy and safety of damoctocog alfa pegol prophylaxis in patients with haemophilia A aged 12-<18 years at enrolment into PROTECT VIII.

Reding MT, Simpson M, Ducore J, Holme PA, Maas Enriquez M, Mancuso ME. Reding MT, et al. Among authors: mancuso me. Acta Haematol. 2024 Apr 10. doi: 10.1159/000538702. Online ahead of print. Acta Haematol. 2024. PMID: 38599195

Noninterventional study assessing joint health in persons with hemophilia A after switching to turoctocog alfa pegol: design of pathfinderReal.

Ay C, Benitez-Hidalgo O, Gidley G, Mancuso ME, Matino D, Nagao A, Nemes L, Waller J, Oldenburg J. Ay C, et al. Among authors: mancuso me. Res Pract Thromb Haemost. 2024 Mar 1;8(2):102363. doi: 10.1016/j.rpth.2024.102363. eCollection 2024 Feb. Res Pract Thromb Haemost. 2024. PMID: 38572481 Free PMC article.

Benefits and risks of non-factor therapies: Redefining haemophilia treatment goals in the era of new technologies.

Mancuso ME, Croteau SE, Klamroth R. Mancuso ME, et al. Haemophilia. 2024 Apr;30 Suppl 3:39-44. doi: 10.1111/hae.14976. Epub 2024 Mar 13. Haemophilia. 2024. PMID: 38481077 Review.

Effect of statin intake on FVIII levels and bleeding outcomes in hypercholesterolemic patients with hemophilia A.

Paciullo F, Momi S, Mancuso ME, Santoro C, Napolitano M, Castaman G, Zanon E, Contino L, De Cristofaro R, Santoro RC, Gresele P. Paciullo F, et al. Among authors: mancuso me. Thromb Res. 2024 Apr;236:167-169. doi: 10.1016/j.thromres.2024.02.028. Epub 2024 Mar 2. Thromb Res. 2024. PMID: 38457995 No abstract available.

Better Communication for Better Management of Persons with Hemophilia: Results from a Patients'-Clinicians' Project to Address the New Therapeutic Landscape.

Banov L, Linari S, Ambroso L, Ferri Grazzi E, Gallo S, Pasqualetti P, Mancuso ME. Banov L, et al. Among authors: mancuso me. J Clin Med. 2024 Jan 19;13(2):568. doi: 10.3390/jcm13020568. J Clin Med. 2024. PMID: 38276074 Free PMC article.

A post hoc analysis of PROTECT VIII kids assessing long-term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A.

Ahuja S, Biss T, Maas Enriquez M, Mancuso ME, Steele M, Kenet G. Ahuja S, et al. Among authors: mancuso me. Eur J Haematol. 2024 May;112(5):756-764. doi: 10.1111/ejh.14167. Epub 2024 Jan 9. Eur J Haematol. 2024. PMID: 38193596

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.

Pipe SW, Collins P, Dhalluin C, Kenet G, Schmitt C, Buri M, Jiménez-Yuste V, Peyvandi F, Young G, Oldenburg J, Mancuso ME, Kavakli K, Kiialainen A, Deb S, Niggli M, Chang T, Lehle M, Fijnvandraat K. Pipe SW, et al. Among authors: mancuso me. Blood. 2024 Apr 4;143(14):1355-1364. doi: 10.1182/blood.2023021832. Blood. 2024. PMID: 38127586 Free PMC article. Clinical Trial.

Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B.

Guillet B, Yan S, Hooper B, Drelich D, Steenkamp J, Tomic R, Mancuso ME. Guillet B, et al. Among authors: mancuso me. Adv Ther. 2024 Feb;41(2):649-658. doi: 10.1007/s12325-023-02745-1. Epub 2023 Dec 9. Adv Ther. 2024. PMID: 38070040 Free PMC article. Clinical Trial.

Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients.

Pabinger I, Lissitchkov T, Nagao A, Lepatan LM, Li Y, Seifert W, Mancuso ME. Pabinger I, et al. Among authors: mancuso me. Res Pract Thromb Haemost. 2023 May 25;7(4):100195. doi: 10.1016/j.rpth.2023.100195. eCollection 2023 May. Res Pract Thromb Haemost. 2023. PMID: 37538501 Free PMC article.

194 results

Page of 20

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

194 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Results by year